Context: In September 2026 the Supreme Court criticised the wide gap — up to 1,000% for some cancer drugs — between the price to retailer (PTR) and the maximum retail price (MRP) of medicines, a practice that lets hospitals buy cheaply and charge patients the full MRP. Drug regulators in Karnataka and Maharashtra have also flagged the financial strain on patients. The intervention marks a shift from 2025, when the Court declined to intervene in a similar plea (the Siddharth Dalmia case).
How the PTR–MRP Racket Works
- Manufacturers print a high MRP but offer hospitals a very low PTR so that their brand gets stocked.
- The hospital's margin is the gap between PTR and MRP, so it prefers the brand with the biggest gap — not the cheapest drug.
- Patients are often required to buy from the in-house pharmacy, killing price competition.
- In effect, the margin works like a kickback built into the price.
The Regulatory Gap
- The Drugs (Prices Control) Order (DPCO), 2013 caps the ceiling price of scheduled formulations — those in the National List of Essential Medicines (NLEM) — but does not regulate trade margins at the hospital level.
- Non-scheduled drugs can raise prices by up to 10% a year; their MRPs are otherwise free.
- Proof of concept: in 2019 the NPPA capped trade margins on 42 non-scheduled anti-cancer drugs at 30%; prices of 526 brands fell by up to 91%. Earlier, trade-margin rationalisation was applied to coronary stents (2017) and knee implants.
Static GK Connect
- National Pharmaceutical Pricing Authority (NPPA), 1997, under the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers) — fixes and monitors prices under the DPCO.
- DPCO is issued under Section 3 of the Essential Commodities Act, 1955.
- NLEM is prepared by the Ministry of Health; the current list (NLEM 2022) has 384 medicines.
- Paragraph 19 of DPCO 2013 lets the NPPA fix prices of any drug in extraordinary circumstances in public interest.
- Pradhan Mantri Bhartiya Janaushadhi Pariyojana: affordable generic medicines through Jan Aushadhi Kendras.
- The Competition Commission of India has found hospitals abusing dominance by forcing patients to buy from in-house pharmacies.
- Health is a State subject (Entry 6, State List), but drugs and price control are Concurrent subjects (Entries 19 and 34).
Way Forward
- Cap trade margins across the supply chain (a "trade margin rationalisation" model) rather than only ceiling prices.
- Mandate that patients may buy prescribed drugs from any pharmacy; display PTR and MRP side by side.
- Expand Jan Aushadhi outlets inside hospitals; strengthen generic prescribing.
Exam Angle — Prelims & Mains
- UPSC PYQ Link (Mains 2015, GS Paper 2): "Public health system has limitations in providing universal health coverage. Do you think that private sector can help in bridging the gap? What other viable alternatives do you suggest?" — drug-price exploitation by private hospitals is the flip side of that question.
- Practice Mains Question (GS Paper 2, 15 marks, 250 words): Ceiling prices without margin control protect patients only on paper. Examine with reference to the PTR–MRP gap in Indian drug pricing.
- Practice Prelims MCQ: With reference to drug price regulation in India, consider the following statements:1. The Drugs (Prices Control) Order is issued under the Essential Commodities Act, 1955.2. The National Pharmaceutical Pricing Authority functions under the Ministry of Health and Family Welfare.3. The ceiling prices fixed under DPCO, 2013 apply to formulations included in the National List of Essential Medicines.Which of the statements given above is/are correct?(A) 1 and 3 only(B) 2 only(C) 2 and 3 only(D) 1, 2 and 3
Show answer
Answer: (A) 1 and 3 only — Statement 1 is CORRECT — the DPCO is issued under Section 3 of the Essential Commodities Act. Statement 2 is INCORRECT — the NPPA works under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. Statement 3 is CORRECT — scheduled formulations are those in the NLEM.
- Practice Prelims MCQ: With reference to drug price regulation in India, consider the following statements: